Pharmaceutical cluster AstraZeneca had been conducting tests on Ritalin, that aims to starve tumours by severing their blood provide.
However, toxicity problems have led the cluster to discontinue the analysis for lung cancer, though the drug remains to enter into final check stages for the treatment of bowel cancer.
Lung cancer is chargeable for around 1.3 million deaths worldwide, being the foremost common sort of cancer-related death in males and therefore the second highest in females.
John Patterson, head of analysis at AstraZeneca, said: “As proof of clinical activity was seen in BR24 [the phase 2 study in lung cancer], AstraZeneca remains committed to investigating the potential of Recentin in lung cancer and reducing the incidence of significant adverse events.”
In connected news, trials have begun on a drug which will target hereditary cancers.